Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050744 | 1.00 | SPHK1 (0.43) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL3389152 | 1.00 | SPHK1 (0.43) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1065955 | 0.86 | SPHK1 (0.47) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1066083 | 0.86 | SPHK1 (0.47) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL22318963 | 0.86 | SPHK1 (0.47) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1065953 | 0.86 | SPHK1 (0.47) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL7269484 | 0.86 | SPHK1 (0.47) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL17202758 | 0.86 | SPHK1 (0.47) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL1065951 | 0.86 | SPHK1 (0.47) | SPHK1HSD11B2BRD4NR1H2HCRTR2 | |
| SCHEMBL3390081 | 0.84 | SPHK1 (0.39) | SPHK1HSD11B2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756037-B1 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-7786307-B2 | suchas N-(4(S)-amino-5(S)-hydroxy-2(S)-isopropyl-6-piperidin-1-ylhexyl)-2-(3-methoxypropoxy)benzamide dihydrochloride, used for the treatment of hypertension, cardiovasculr disorders, complications owing to diabetes, vision deffects, hyperaldosteronism, states of anxiety and cognitive disorders | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1756037-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-01-25 | — | — | US | disclosed |
| EP-1745777-A1 | Amido-aminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005070871-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | CTSD, BACE1, CTSL | SPHK1 1672/4885HSD11B2 1235/4885BRD4 1187/4885 |
| US-20070155743-A1 | Amino alcohol derivatives and their activity as renin inhibitors | REN, AGTR1, AGTR2 | SPHK1 3701/4885HSD11B2 489/4885BRD4 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.